What is ATS's gross profit margin?

What is the revenue and EPS growth rate for ATS year over year?

What is the market's earnings forecast for ATS next quarter?

Did ATS beat or miss consensus estimates last quarter?

What were the key takeaways from ATS's earnings call?

What is ATS's latest dividend and current dividend yield?

What factors drove the changes in ATS's revenue and profit?

What does ATS do and what are its main business segments?

- **CEO Vision**: Margin expansion through lean ops, ABM tools, and strategic M&A. New leaders in high-growth end markets.
- **Strong Q3 Results**: Revenue +17%, EBIT +21.6%, despite lower gross margin from program mix.
- **Growth Drivers**: Nuclear (SMR/refurbishment), life sciences (radiopharma), and consumer automation. Transportation cautious on EV projects.
- **Financial Discipline**: 3x leverage, working capital efficiency, and $20M restructuring for growth reinvestment.

**【CEO Summary Section】**
- **New Strategic Focus**: CEO Doug Wright emphasizes margin expansion, lean operations, and disciplined capital allocation. Key priorities include improving gross margin through ABM (Advanced Business Management) tools, aftermarket mix growth, and strategic M&A.
- **Leadership Appointments**: New executives in Life Sciences (Sarah Moore) and Packaging/Food (Simon Roberts) to strengthen end-market alignment and recurring revenue streams.
- **Market Outlook**: Optimism in nuclear (SMR and refurbishment), life sciences (radiopharma, GLP-1), and consumer automation, with caution in transportation due to project risk assessment.

**【CFO Financial Commentary】**
- **Q3 Financials**: Order bookings $821M (+12% QoQ), revenue $761M (+17% YoY), adjusted EBIT $79.9M (+21.6% YoY). Gross margin 29.6% (-111bps YoY) due to program mix.
- **Backlog & Outlook**: $2.1B backlog (1.06x book-to-bill). Q4 revenue guidance $710M-$750M, with FY26 organic growth ~8% and EBIT up 14% YoY.
- **Leverage & Efficiency**: Net debt/EBITDA 3x (target 2-3x). Working capital improved to 16.4% of revenue, targeting <15%.

**【Q&A Highlights】**
- **Margin Expansion**: Focus on ABM, aftermarket, and R&D for high-margin solutions. Restructuring costs $20M (payback period unchanged) with reinvestment in growth areas.
- **End Market Trends**: Nuclear (SMR + refurbishment) and life sciences (radiopharma) driving growth. Transportation cautious on EV projects, focusing on niche opportunities.
- **M&A Strategy**: Disciplined deployment of capital in 2-3x leverage range, prioritizing tech/synergy fits with existing end markets.
- **FX Impact**: 4.1% revenue boost from CAD/USD, 11% SG&A increase YoY due to FX.

ATS Corporation (ATS) Q3 2026 Earnings Call Transcript

- **Cash Flow Recovery**: Operating free cash flow turned positive (+€125M vs. -€345M YoY), signaling financial turnaround.
- **Revenue Growth**: €846M (+6% YoY, +11% in USD), IC substrates up 19% YoY in EUR, driven by AI and server demand.
- **Profitability**: EBITDA margin 21% (€175M), Q2 EBIT breakeven, 2026 guidance for €391M EBITDA (23% margin).
- **Cost Efficiency**: AURORA program delivered €150M+ savings, supporting 2026+ cost competitiveness.
- **Customer Diversification**: 15+ key IC substrate customers, reducing reliance on a few clients; PCB key customers up 30% in revenue share.
- **T-Glass Supply**: Actively qualifying alternatives, no immediate shortage but long-term growth risks; supplier partnerships progressing.
- **New Plant Progress**: Kulim site ramping with existing equipment, potential for stepwise expansion; Hinterberg site generating classical revenue.
- **China Strategy**: Local-for-local production in Chongqing to mitigate trade risks, power electronics focus.
- **AI & Power Electronics**: Embedding components in substrates (e.g., AMD partnership), power electronics growth driver with 2026+ revenue contribution.


**【CEO Summary Section】**
- **Cash Flow Turnaround**: Operating free cash flow improved from -€345M to +€125M YoY, signaling financial recovery.
- **Revenue Growth**: €846M (H1 2025/26) vs. €800M prior, +6% in EUR, +11% in USD, driven by IC substrates (+19% YoY in EUR).
- **Profitability**: EBITDA margin rose to 21% (€175M vs. €157M), with Q2 EBIT breakeven achieved.
- **Cost Savings**: AURORA program exceeded targets, delivering €150M+ savings vs. €130M goal, supporting 2026+ cost efficiency.
- **Customer Diversification**: 15+ key IC substrate customers, reducing reliance on a few clients; PCB key customers up 30% in revenue share.
- **T-Glass Supply**: Actively qualifying alternative suppliers, with no immediate shortage but long-term growth concerns; supplier partnerships and customer collaboration ongoing.
- **New Plant Progress**: Kulim site ramping with existing equipment, potential for stepwise expansion; Hinterberg site generating classical revenue.

**【CFO Financial Commentary】**
- **Revenue & Profitability**: €846M (+6% YoY), EBITDA €175M (21% margin), operating cash flow €209M (vs. €186M prior).
- **Balance Sheet**: Net debt €1.4B (stable), net debt/EBITDA 2.2x, financial flexibility maintained with €811M unused credit lines.
- **Guidance**: FY25/26: €1.7B rev, 23% EBITDA margin (€391M), +20%+ growth in USD; FY26/27: €2.1-2.4B rev, 20%+ EBITDA margin.

**【Q&A Highlights】**
- **T-Glass Qualification**: Actively testing alternatives, supplier partnerships progressing; no immediate shortage but long-term growth risks.
- **Kulim Plant**: Stepwise ramp using existing equipment, potential for new contracts in 2026; embedding capabilities a key differentiator.
- **AI & Power Electronics**: Embedding components in substrates (e.g., AMD partnership), power electronics growth driver with 2026+ revenue contribution.
- **China Strategy**: Local-for-local production in Chongqing to mitigate US-China trade risks, solid-state power electronics focus.
- **Market Trends**: Server/AI infrastructure demand strong, automotive exposure limited; 2025/26 substrate CAGR 29% YoY, 2026+ growth cautious due to industry uncertainty.


ATS Corp (ATS) Q2 2026 Earnings Call Transcript

- **Revenue Growth**: 6% YoY to $737M, driven by acquisitions and FX, with stable backlog ($2.1B) supporting full-year growth.
- **Life Sciences Strength**: Auto-injectors and radiopharma dominate, with Comecer expansion supporting radio pharma.
- **Energy Momentum**: CANDU refurbishment and nuclear decommissioning (Multiplex system) drive $229M backlog.
- **Margin Improvement**: Sequential operating margin up 40bps to 10.7%, with medium-term gross margin expansion via services and productivity.
- **Strategic Focus**: Services portfolio expansion, innovation in VR training, and ABM model for margin improvement.
- **Financial Health**: Net debt/EBITDA 3.6x (target 2-3x), with $156M cash flow and $194M EV settlement reducing debt.

**【CEO Summary Section】**
- **Revenue Growth**: Q1 revenue of $737 million, up 6% YoY, driven by acquisitions and foreign exchange benefits. Organic growth was -1.2% due to lower transportation revenues.
- **Order Bookings**: $693 million, down 15% YoY, with trailing 12-month book-to-bill ratio of 1.17:1, supporting full-year growth outlook.
- **Backlog**: $2.1 billion, up 6% YoY in Food & Beverage and stable in Life Sciences ($1.2 billion), reflecting diversified opportunities.
- **Market Highlights**: 
  - **Life Sciences**: Auto-injectors, radiopharma, and wearables dominate, with Comecer's Indianapolis expansion supporting radio pharma.
  - **Food & Beverage**: Strong aftermarket service demand, with Paxiom integration driving secondary processing growth.
  - **Energy**: CANDU refurbishment activity and nuclear decommissioning (Multiplex system) drive $229 million backlog.
  - **Consumer Products**: Stable with warehouse automation and niche opportunities.
- **Strategic Initiatives**: Services portfolio expansion (e.g., Connected Care Hub), innovation in VR training, and ABM model for margin improvement.
- **Recognition**: Named #1 in Canada's Best Companies 2025 for engineering/manufacturing.

**【CFO Financial Commentary】**
- **Revenue**: $737 million (+6.1% YoY), with 4.1% from acquisitions and 3.2% FX benefit. Adjusted EBITDA of $78.6 million (10.7% margin).
- **Margins**: Gross margin stable at 29.8%, SG&A up $20 million YoY due to acquisitions and FX. Sequential operating margin improved by 40bps.
- **Liquidity**: $156 million operating cash flow, $16.3 million CapEx, and $194 million EV settlement reducing debt.
- **Balance Sheet**: Net debt/EBITDA 3.6x (target 2-3x). Free cash flow used for share buybacks and deleveraging.
- **Outlook**: Q2 revenue $700-740 million, full-year growth and margin expansion on track despite non-linear progress.

**【Q&A Highlights】**
- **Demand Environment**: Healthy funnel across markets; Life Sciences resilient despite U.S. lab funding slowdown (low single-digit exposure). Energy nuclear activity strong, offsetting SMR delays.
- **Tariffs Impact**: Minimal impact on U.S./Canada trade (USMCA-covered exports). Customers cautious on cross-border investments.
- **M&A Integration**: Avidity, Heidolph, and BioDot integration on track, with ABM adoption driving cost synergies.
- **Margins**: Medium-term gross margin expansion via life sciences mix, services, and productivity initiatives. Q2 margin may lag due to project mix.
- **Multiplex System**: Patent-protected nuclear decommissioning tool with growing backlog, exemplifying ATS's innovation in regulated markets.
- **Deleveraging**: Target 2-3x leverage by end-2026 via working capital optimization (15% of rev target).

ATS Corporation (ATS) Q1 2026 Earnings Call Transcript

- **Q4 Bookings Beat Expectations**: $863M (+9% YoY), full-year $3.3B record, with life sciences backlog at $1.2B. 
- **Backlog Visibility**: $2.1B (19% YoY), 1.23:1 book-to-bill, 23% >1 year. 
- **EV Settlement Boost**: $134.7M payment cuts leverage by 0.5x, enabling M&A flexibility. 
- **Gross Margin Improvement**: 29% (up 90bps), driven by high-margin programs. 
- **FY26 Growth Path**: Transportation restructuring, life sciences ramp-up, and diversified backlog support return to organic growth. 
- **Key Risks**: Macro uncertainty, working capital intensity in product businesses, and EV market volatility. 


**【CEO Summary Section】**
- **Record Q4 Order Bookings**: $863 million, up 9% YoY, driven by organic growth (2.6%), acquisitions (4%), and FX (2.5%). Full-year bookings hit $3.3 billion, a 14.3% increase, with life sciences and energy leading. 
- **Backlog Strength**: $2.1 billion at quarter-end, highest in 8 quarters, with 1.23:1 trailing 12-month book-to-bill ratio. Life sciences backlog reached $1.2 billion, supported by GLP-1 drugs, wearables, and radiopharma. 
- **Market Resilience**: Despite macro uncertainty, all verticals maintained >1.0 book-to-bill. Transportation bookings rebounded with a European EV customer win. 
- **Strategic Initiatives**: 
  - $134.7M EV settlement resolved, reducing leverage by 0.5x. 
  - M&A pipeline active (e.g., Paxiom, Heidolph) to expand product portfolio. 
  - ABM tools and digital solutions (e.g., Symphoni, Digital Tomato) driving efficiency. 

**【CFO Financial Commentary】**
- **Q4 Financials**: 
  - Adjusted revenue: $721M (-8.9% YoY) due to lower EV volumes. 
  - Adjusted EBIT: $74M (-23% YoY), impacted by transportation margins. 
  - Gross margin improved 90bps to 29% from mix shift to higher-margin programs. 
- **Key Metrics**: 
  - FY25 backlog up 19.3% to $2.1B, with 23% extending beyond 1 year. 
  - Working capital (non-cash) at 15.1%, targeting <15%. 
  - EV settlement to reduce Q1 FY26 leverage to ~3.4x from 3.9x. 
- **Outlook**: 
  - Q1 FY26 revenue $680-730M, with sequential growth. 
  - Margin expansion in FY26 via life sciences ramp-up and EV restructuring. 
  - CapEx $80-100M for innovation in Symphoni, SuperTrak, and food/beverage digital tools. 

**【Q&A Highlights】**
- **Organic Growth Confidence**: 1.23 book-to-bill ratio and diversified backlog (23% >1 year) support FY26 return to growth. 
- **Life Sciences Sustainability**: 8+ GLP-1 customers, radiopharma wins, and wearables driving $1.2B backlog. 
- **Working Capital Optimization**: Transportation share shrinking (15% target) offset by product-based businesses (e.g., Heidolph). 
- **Tariff Mitigation**: Global supply chain flexibility and USMCA compliance limit impact. 
- **EV Business Reset**: Rightsized to factory automation, with potential in small modular reactors. 
- **M&A Discipline**: Target 2.0-3.0x leverage; cultivate deals with 12-18-month payback. 
- **Tax Rate**: Mid-20% going forward, with benefits from legal entity consolidation. 


Actual	0.5205	0.4637	0.4904	0.4798	0.3654	0.1848	0.2224	0.2849	0.3011	0.3231	0.35
Forecast	0.4893	0.4711	0.4791	0.4155	0.3833	0.2466	0.2427	0.2632	0.3233	0.3111	0.318
Surprise	+6.38%	-1.57%	+2.36%	+15.48%	-4.67%	-25.06%	-8.36%	+8.24%	-6.87%	+3.86%	+10.06%

Actual	568.55M	541.56M	567.38M	584.29M	507.33M	452.89M	453.07M	501.01M	541.11M	523.03M	553.81M
Forecast	544.87M	528.41M	552.47M	532.94M	508.13M	473.64M	452.46M	481.32M	523.11M	518.05M	526.11M
Surprise	+4.35%	+2.49%	+2.70%	+9.63%	-0.16%	-4.38%	+0.14%	+4.09%	+3.44%	+0.96%	+5.26%

ATS

ATS fundamentals

ATS Q3 2026 Earnings

Earnings Call

You can ask Aime

ATS

ATS fundamentals

ATS Q3 2026 Earnings

Earnings Call

ATS Earnings Call Summary for Q3/20268:30 AM on Feb 4, 2026

ATS Earnings Call Summary for Q2/20268:30 AM on Nov 5, 2025

ATS Earnings Call Summary for Q1/20268:30 AM on Aug 7, 2025

ATS Earnings Call Summary for Q4/20256:00 PM on May 28, 2025

ATS Earnings Call Summary for Q3/2025 Mar 25, 2026

You can ask Aime